GSK plc files 6-K

GSK plc announced that China's National Medical Products Administration (NMPA) has approved Exdensur (depemokimab) for the treatment of severe asthma with an eosinophilic phenotype in adult and pediatric patients aged 12 years and older. This approval is based on SWIFT trials showing significantly lower rates of exacerbations in patients receiving depemokimab versus placebo.